Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.


Why this Research Matters

Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.


Who can Participate

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study.


Study ID

Protocol Number: 24-2391

More information available at ClinicalTrials.gov: NCT06074510


Meet the Team

Image of Principal Investigator

Paul Maroni, MD

Principal Investigator